Inveltys (loteprednol etabonate ophthalmic suspension; Kala) 1% has been made available for the treatment of postoperative inflammation and pain following ocular surgery.

Inveltys is the first ocular steroid approved for twice-daily dosing for this indication; other ocular steroids are approved for 4 times daily dosing. The product utilizes the Company’s proprietary AMPPLIFY Mucus-Penetrating Particle technology to improve penetration into target tissues of the eye. The technology has demonstrated a greater delivery of the drug into ocular tissues vs current loteprednol etabonate-containing drugs. Data from two Phase 3 studies showed a greater proportion of patients treated with Inveltys having complete resolution of ocular inflammation and pain compared with placebo.

Inveltys is a sterile preserved ophthalmic suspension containing 10mg/mL of loteprednol etabonate and is supplied as 2.8mL in a 5mL bottle. The product contains the preservative benzalkonium chloride 0.01%, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of drops and may be reinserted after 15 minutes following administration.

Related Articles

Follow @ClinicalPainAdv

For more information visit Inveltys.com.

This article originally appeared on MPR